UK markets open in 1 hour 10 minutes
NIKKEI 225
27,116.77 -194.53 (-0.71%) HANG SENG
17,728.63 -283.52 (-1.57%) CRUDE OIL
88.25 -0.20 (-0.23%) GOLD FUTURES
1,720.20 -0.60 (-0.03%) DOW
29,926.94 -346.96 (-1.15%) BTC-GBP
17,884.32 -391.45 (-2.14%)
Sareum Holdings plc (SAR.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 05:08PM BST
| Previous close | 207.50 |
| Open | 205.00 |
| Bid | 210.00 x 0 |
| Ask | 225.00 x 0 |
| Day's range | 205.00 - 224.88 |
| 52-week range | 92.50 - 377.50 |
| Volume | |
| Avg. volume | 85,161 |
| Market cap | 148.051M |
| Beta (5Y monthly) | -0.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.70 |
| Earnings date | 31 Oct 2022 - 04 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 304.00 |
- Globe Newswire
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Sareum Holdings PLC (“Sareum” or the “Company”) Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update Clinical Trial Authorisation application for a Phase 1a/b clinical trial with SDC-1801 submitted to the UK Medicines and Healthcare Products Regulatory AgencySareum has made significant progress advancing SDC-1801 towards clinical development and plans to initiate Phase 1 clinical trials in 2022, with
- Simply Wall St.
What Is The Ownership Structure Like For Sareum Holdings plc (LON:SAR)?
The big shareholder groups in Sareum Holdings plc ( LON:SAR ) have power over the company. Generally speaking, as a...
- Simply Wall St.
Companies Like Sareum Holdings (LON:SAR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Sareum Holdings ( LON:SAR...
© 2022 Yahoo. All rights reserved.
